Conclusion
obesity, HR+
OBESITY, OBESE
In this study among 1781 HR+ BC patients, overweight and obesity were adverse prognostic factors for DFS. BMI did not impact the efficacy of extended anastrozole.One in five women worldwide are estimated to be obese by 2025 (In the general population, however, the association between obesity and all-cause mortality tends to differ between younger and older adults (Over the years, the impact of BMI on the efficacy of (extended) endocrine therapy has also been studied in postmenopausal women with HR+ BC. Tamoxifen seems to be equally effective across BMI classes (The present post hoc study was performed within the framework of the DATA study, a randomized controlled trial that evaluated the efficacy of 6 versus 3 years of anastrozole after 2 to 3 years of adjuvant tamoxifen in postmenopausal women with HR+ BC (